Vir Biotechnology reports Q2 EPS (80c), consensus (72c)

“We achieved several important milestones across our pipeline, reflecting our commitment to our mission of powering the immune system to transform lives,” said Marianne De Backer, Chief Executive Officer, Vir Biotechnology (VIR). “The initiation of our Phase 1 study of PRO-XTEN(TM) dual-masked VIR-5525 positions us to potentially address the shortcomings of available treatment options across multiple EGFR-expressing solid tumors. The universal PRO-XTEN(TM) masking technology represents a next-generation approach to cancer treatment, designed to expand the therapeutic index of T-cell engagers. We now have three clinical trials of PRO-XTEN(TM) masked T-cell engagers ongoing, supported by promising early clinical data for VIR-5818 and VIR-5500, and we are leveraging insights from our ongoing programs to efficiently execute clinical trials and expand our oncology portfolio. Additionally, our ECLIPSE registrational program is now fully underway, and we are advancing toward a potentially highly effective, well-tolerated and convenient treatment option for patients with chronic hepatitis delta.”